奥瓦多胺通过通过向葡萄糖-6-酸盐脱酶调节新陈代谢重编程来缓解纤维化
Xiaoyang He1, Xiaowen Chen1, Wenting Wu1
1Department of Nephrology, Zhujiang Hospital, Southern Medical University, Guangzhou, PR China.
概括
二醇 (Ova) 通过选择性抑制葡萄糖-6-酸脱酶 (G6PD) 来治疗纤维化 (RF) 是有前途的. 这种有针对性的方法为慢性病 (CKD) 提供了一个新的治疗策略.
科学领域:
- 生物化学 生化学
- 药理学 药理学是指药理学的学科.
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 纤维化 (RF) 是慢性病 (CKD) 的常见并发症,目标治疗有限.
- 二化物 (Ova) 是一种来自Anisomeles indica的化合物,在脏健康方面具有传统用途.
研究的目的:
- 为了研究Ova对RF的治疗作用.
- 阐明Ova作用的潜在分子机制,重点关注代谢重编程.
主要方法:
- 在小鼠中使用单边缺血-再输伤 (UIRI) 和单边尿道阻塞 (UUO) 模型的体内研究.
- 使用基因操纵的管状上皮细胞 (RTEC) 的体外研究 (siRNA,突变质粒).
- 生物化学分析包括质谱 (MS),HuProtTM蛋白质组微阵列,表面等离子体共振 (SPR) 和分子对接,以确定Ova的目标和机制.
主要成果:
- 在小鼠模型中,通过抑制酸通路 (PPP),卵子治疗显著降低了RF.
- 卵子在 Lys403 处选择性地与 G6PD 结合并乙化,在不影响蛋白质表达的情况下抑制其活性.
- 这种选择性抑制保持了基底PPP水平,这对于细胞生存至关重要.
结论:
- 通过选择性G6PD调制,Ova被确定为RF的潜在治疗剂.
- 这些发现支持开发针对RF的代谢向疗法.
- 这项研究为治疗病提供了重要的科学和翻译价值.
更多相关视频
06:54Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
13.3K
10:31Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
287
相关概念视频
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
309
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
309
01:23Dipeptidyl Peptidase 4 Inhibitors
270
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
270